PALATIN TECHNOLOGIES INC (PTN) stock: key figures, P/E, revenue and dividend

Health Care · United States · ISIN US6960776010

Price
6.23 USD
Market cap
11.10 m USD
P/E (2026)
–
P/S (2026)
1.26
Dividend yield
0.00 %
Net margin
-94.88 %
Return on equity (ROE)
-125.30 %
Return on assets (ROA)
-98.29 %

PALATIN TECHNOLOGIES INC financials

Fiscal year20252026
Revenue0.00 USD8.83 m USD
Operating income-17.46 m USD-8.67 m USD
EBIT-17.29 m USD-16.75 m USD
Net income-17.31 m USD-8.38 m USD
Diluted EPS – continuing operations-32.15 USD-2.96 USD

Full history since 1996, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About PALATIN TECHNOLOGIES INC

Palatin Technologies, Inc., a biopharmaceutical company, develops first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system in the United States. It is developing oral small molecule PL7737 MC4R agonist in preclinical studies; long-acting peptide MC4R agonists; and Bremelanotide co-administration with Tirzepatide to treat obesity in Phase 2 trial, as well as Bremelanotide co-formulated with a PDE5i for the treatment of ED in patients not adequately responsive to PDE5i monotherapy. The company also develops PL9643 for dry eye disease and anti-inflammatory ocular indications; and oral PL8177 for the treatment inflammatory bowel diseases. Palatin Technologies, Inc. was incorporated in 1986 and is based in Monmouth Junction, New Jersey.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 13.11.2026. Details in the risk notice.